Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Yun-Ai Su ◽  
Chad A. Bousman ◽  
Qi Liu ◽  
Xiao-Zhen Lv ◽  
Ji-Tao Li ◽  
...  
2015 ◽  
Vol 16 (17) ◽  
pp. 1919-1929 ◽  
Author(s):  
Malgorzata Maciukiewicz ◽  
Victoria S Marshe ◽  
Arun K Tiwari ◽  
Trehani M Fonseka ◽  
Natalie Freeman ◽  
...  

2019 ◽  
Vol 50 (10) ◽  
pp. 1644-1652 ◽  
Author(s):  
Sorana C. Iancu ◽  
Yak Mee Wong ◽  
Didi Rhebergen ◽  
Anton J. L. M. van Balkom ◽  
Neeltje M. Batelaan

AbstractBackgroundMajor depressive disorder (MDD) represents a leading cause of disability. This study examines the course of disability in patients with chronic, recurrent and remitting MDD compared to healthy controls and identifies predictors of disability in remitting MDD.MethodsWe included 914 participants from the Netherlands Study of Depression and Anxiety (NESDA). DSM-IV MDD and WHO DAS II disability were assessed at baseline and at 2, 4 and 6 years. Six-year total and domain-specific disability were analysed and compared in participants with chronic (n = 57), recurrent (n = 120), remitting (n = 127) MDD and in healthy controls (n = 430). Predictors of residual disability were identified using linear regression analysis.ResultsAt baseline, most disability was found in chronic MDD, followed by recurrent MDD, remitting MDD and healthy controls. Across diagnostic groups, most disability was found in household activities, interpersonal functioning, participation in society and cognition. A chronic course was associated with chronic disability. Symptom remission was associated with a decrease in disability, but some disability remained. In remitting MDD, higher residual disability was predicted by older age, more severe avoidance symptoms, higher disability at baseline and late symptom remission. Severity of residual disability correlated with the severity of residual depressive symptoms.ConclusionsSymptomatic remission is a prerequisite for improvements in disability. However, disability persists despite symptom remission. Therefore, treatment of MDD should include an explicit focus on disability, especially on the more complex domains. To this end, treatments should promote behavioural activation and address subthreshold depressive symptoms in patients with remitted MDD.


2021 ◽  
pp. 329-344
Author(s):  
Lisa Brown ◽  
Chelsea Cockburn ◽  
Harris A. Eyre

Major depressive disorder (MDD) is a leading cause of disability worldwide, and over half of patients do not achieve symptom remission following an initial antidepressant course. Despite rigorous research, our understanding of the pathophysiology of MDD and response to MDD treatments is limited. An emerging field of interest in psychiatry is that of the interaction of mental illness and the microbiome. This new field also allows for the study of the effect of the microbiome on treatment response, or pharmacomicrobiomics (PMx). PMx, in addition to other tools like pharmacogenetics and pharmacoepigenetics, has the potential to inform treatment selection for individuals suffering from MDD and truly personalizing care for the disorder. Here, we discuss the current evidence for PMx as well as a potential future roadmap.


Sign in / Sign up

Export Citation Format

Share Document